AVR: רווח נקי למניה (EPS TTM) Anteris Technologies Ltd

Anteris Technologies Global revenue is based on the implementation of biomimetic prostheses for cardiac surgery. This 12-month net income per share chart visualizes this trajectory, where the -1.61 indicator expresses the state of the metric. The development of the DurAVR valve and expected FDA approval create growth potential. High demand from centers for the unique hemodynamics of the devices expands the company's market reach.

This indicator measures the rolling annual profit per share, adjusted for changes in the volume of issuance, which allows for an assessment of real capital generation efficiency without accounting for equity dilution. By analyzing the current rolling annual net income per share, an investor can compare the financial stability of Anteris Technologies Global (AVR) with the commercialization potential of their unique 3D heart valve models.